<sup>68</sup>Ga-FAPI-46 PET/CT in the evaluation of gliomas: comparison with <sup>18</sup>F-FDG PET/CT and contrast-enhanced MRI
<b><i>Rationale:</i></b> This study compared <sup>68</sup>Ga-FAPI-46 PET/CT, <sup>18</sup>F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced MRI (CE-MRI) for glioma imaging, classification, and recurrence detection and explored PET parameters and molecular pathological profiles. <b><i>Methods:</i></b> Between June 2020 and June 2024, we prospectively enrolled patients with space-occupying lesions in the brain or previously treated gliomas. All patients underwent sequential CE-MRI, <sup>68</sup>Ga-FAPI-46, and <sup>18</sup>F-FDG PET/CT. Diagnostic accuracy was assessed based on a reference standard, and PET parameters were analysed for correlations with WHO grading and molecular characteristics. <b><i>Results:</i></b> Forty-eight patients (median age, 51 years; 32 men) with 40 confirmed gliomas were enrolled. For primary tumour diagnosis, the sensitivity of <sup>68</sup>Ga-FAPI-46 PET/CT was equivalent to CE-MRI (95% vs. 100%, <i>P</i> = 0.99) and <sup>18</sup>F-FDG PET/CT (95% vs. 77%, <i>P</i> = 0.13). <sup>68</sup>Ga-FAPI-46 uptake was higher in grade IV than in grade I-II gliomas (5.03 vs. 1.14, <i>P</i> = 0.02). <sup>68</sup>Ga-FAPI-46 PET/CT showed significantly higher maximum standardized uptake value and tumour-to-background ratio (TBR) in recurrent tumours than in treatment-related changes and demonstrated favourable sensitivity and specificity for detecting recurrent gliomas, though not significantly superior to <sup>18</sup>F-FDG PET/CT (sensitivity: 100% vs. 85%, <i>P</i> = 0.48; specificity: 100% vs. 80%, <i>P</i> = 0.99) and CE-MRI (sensitivity: 100% vs. 100%, <i>P</i> = NA; specificity: 100% vs. 40%, <i>P</i> = 0.25). Glial fibrillary acidic protein-mutant gliomas exhibited higher <sup>68</sup>Ga-FAPI-46 uptake than wild-type gliomas. <b><i>Conclusion:</i></b> <sup>68</sup>Ga-FAPI-46 PET/CT outperformed <sup>18</sup>F-FDG and CE-MRI in diagnosing glioma recurrence, although the results were not statistically significant. For primary glioma diagnosis, <sup>68</sup>Ga-FAPI-46 PET/CT, despite having a better TBR, did not surpass <sup>18</sup>F-FDG PET/CT and CE-MRI in terms of sensitivity and specificity. However, <sup>68</sup>Ga-FAPI-46 PET/CT is superior to <sup>18</sup>F-FDG for visualizing and classifying gliomas.
Authors
- Haojun Chen (ORCID: https://orcid.org/0000-0002-9101-8884)
- Dan Ruan (ORCID: https://orcid.org/0000-0003-3400-7684)
- Yizhen Pang (ORCID: https://orcid.org/0000-0001-7710-5925)
- Liang Zhao (ORCID: https://orcid.org/0000-0002-3489-7421)
- Long Sun (ORCID: https://orcid.org/0000-0002-0318-2925)
- Changjing Zuo
- Chengkun Han
- Jiayu Cai (ORCID: https://orcid.org/0000-0002-7041-0342)
- Lingyu Yu (ORCID: https://orcid.org/0000-0003-4322-9924)
- Guowei Tan (ORCID: https://orcid.org/0000-0003-4174-0382)
- Xiaobo Qu
- Zhanxiang Wang
- Jian‐Ping Sun (ORCID: https://orcid.org/0009-0001-7473-1696)
Institutions
- Second Military Medical University (CN)
- Xiamen University (CN)
- Chinese Academy of Sciences (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Xiamen Institute of Rare-earth Materials (CN)
- Changhai Hospital (CN)
Publication Details
- Journal
- Theranostics
- Published
- 2024-10-21
- DOI
- https://doi.org/10.7150/thno.103399
- Citations
- 17
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 4.80
Funders
- National Natural Science Foundation of China